Cross-source identity
National Provider Identifier 1154633808 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1154633808 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1154633808 | 80 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1154633808 | 40 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity c1a8ae11… | Canonical resolved node · 4 identifier(s) · 0 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,709 | 13 |
| Consulting Fee | $10,950 | 2 |
| Travel and Lodging | $5,964 | 27 |
| Food and Beverage | $1,276 | 37 |
| Honoraria |
| Manufacturer | Amount | Records |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $32,762 | 27 |
| Lilly Usa, Llc | $30,576 | 33 |
| Lundbeck Llc | $883 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Nuplazid(Pimavanserin Tartrate) | 57 | $307,370 |
| Rexulti(Brexpiprazole) | 89 | $118,720 |
| Galantamine Er(Galantamine Hbr) | 343 | $25,174 |
| Adlarity(Donepezil Hcl) | 56 | $24,773 |
| Rivastigmine | 176 | $17,691 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| 1 |
| 3 |
| Acadia Pharmaceuticals Inc | $300 | 12 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $120 | 2 |